CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation

NCT04987268 | Completed

• 1 other identifier: CHIP RETENTION V1.0
• Study Type: observational
• Target: 1,029
• Locations: 1 country
• Sites: 1

Brief Summary

In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete revascularization and perform whole-exome sequencing for enrolled patients to identify the prevalence of CHIP mutations. After 1-year follow-up, the relationship of presence of CHIP mutations and the occurrence of MACCEs will be explored, irrespective of smoking cessation or not. CHIP may be a potential risk factor of poor prognosis of ACS.

Conditions

ACS; Clonal Hematopoiesis of Indeterminate Potential; Smoking Cessation

Outcome Measures

Primary Outcomes (1)

• prevalence of CHIP mutations

  Whole-exome sequencing is performed to detect the presence of CHIP mutations

  24 hours

Secondary Outcomes (1)

• MACCE

  1 year

Study Arms (3)

Current-smoking

exposure: smoking

Genetic: clonal hematopoiesis of indeterminate potential

Smoking-cessation

exposure: smoking cessation

Genetic: clonal hematopoiesis of indeterminate potential

non-smoking

exposure: none

Genetic: clonal hematopoiesis of indeterminate potential

Interventions

clonal hematopoiesis of indeterminate potential GENETIC

Whole-exome sequencing is performed to detect the presence of clonal hematopoiesis of indeterminate potential (CHIP)

Current-smoking; Smoking-cessation; non-smoking

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

ACS patients undergoing complete revascularization

You may qualify if:

• \. In-patients with acute coronary syndrome to undergo PCI 2. Complete revascularization during the index hospitalization 3. Written informed consent

You may not qualify if:

• \. Periprocedural complications (coronary artery dissection, perforation, myocardial infarction, stroke, death) 2. Planned coronary revascularization at discharge 3. Patients with severe chronic disease (uremia, liver cirrhosis, COPD (chronic obstructive pulmonary disease) 4. Abnormal blood counts caused by hematological diseases 5. Diagnosed malignancy

Sponsors & Collaborators

• Shenyang Northern Hospital: lead

Study Sites (1)

General Hospital of Shenyang Military Region

Shenyang, Liaoning, 110016, China

Location

MeSH Terms

Conditions

Smoking Cessation

Interventions

Clonal Hematopoiesis

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Intervention Hierarchy (Ancestors)

Hematopoiesis; Cell Differentiation; Cell Physiological Phenomena; Clonal Evolution; Genetic Phenomena; Blood Physiological Phenomena; Circulatory and Respiratory Physiological Phenomena

Study Officials

• Yaling Han, MD

  The General Hospital of Northern Theater Command

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of cardiology, Shenyang Northern Hospital

Study Record Dates

• First Submitted: July 28, 2021
• First Posted: August 3, 2021
• Study Start: August 20, 2021
• Primary Completion: August 20, 2022
• Study Completion: August 20, 2023
• Last Updated: September 10, 2025

Record last verified: 2025-09

Locations

CN (1)